Avacta Group PLC (AVCT)

Industry Biotechnology

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

77.00p

Buy

78.00p

arrow-up3.00p (+3.95%)

Prices updated at 26 Jun 2026, 16:35 BST

Prices minimum 15 mins delay

Prices in GBX

Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation prote ...

FTSE All-Share

-0.19%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Mr. Richard Ian Hughes

CEO

Dr. Christina Marie Coughlin

Most recent earnings

31 Dec 2025

Fiscal year end

31 Dec 2025

Employees

75

Head office

58 Wood Lane

London

United Kingdom

W12 7RZ

+44 2039110353

investors@avacta.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Richard Ian Hughes Non-Executive Director, Chairman	-
Ms. Darlene Marie Deptula-Hicks Non-Executive Director	-
Mr. Paul Andrew Fry Non-Executive Director	-
Mr. David John Bryant Non-Executive Director	-
Dr. Christina Marie Coughlin Executive Director, Chief Executive Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
AXA Investment Managers UK Ltd	4,758,156
UTM IM GBP AXA Framlington Biotech	4,758,156
Unicorn Asset Management Ltd	4,300,000
Unicorn AIM VCT Series 3 ORD	4,300,000
FIL Life Insurance Limited	2,379,070

Director dealings

Date chevron-l-regular chevron-r-regular	Action
No data

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.